Form 8-K
8-K — JOHNSON & JOHNSON
Accession: 0000200406-26-000155
Filed: 2026-07-28
Period: 2026-07-27
CIK: 0000200406
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Regulation FD Disclosure
Item: Financial Statements and Exhibits
Documents
8-K — jnj-20260727.htm (Primary)
EX-99.1 (exhibit991.htm)
GRAPHIC (image_0a.jpg)
GRAPHIC (image_1a.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: jnj-20260727.htm · Sequence: 1
jnj-20260727
0000200406false00002004062026-07-272026-07-270000200406us-gaap:CommonStockMember2026-07-272026-07-270000200406jnj:A1.150NotesDueNovember2028Member2026-07-272026-07-270000200406jnj:A2.700NotesDueFebruary2029Member2026-07-272026-07-270000200406jnj:A3.20NotesDueJune2032Member2026-07-272026-07-270000200406jnj:A3.050NotesDueFebruary2033Member2026-07-272026-07-270000200406jnj:A1.650NotesDueMay2035Member2026-07-272026-07-270000200406jnj:A3.350NotesDueJune2036Member2026-07-272026-07-270000200406jnj:A3.350NotesDueFebruary2037Member2026-07-272026-07-270000200406jnj:A3.550NotesDueJune2044Member2026-07-272026-07-270000200406jnj:A3.600NotesDueFebruary2045Member2026-07-272026-07-270000200406jnj:A3.700NotesDueFebruary2055Member2026-07-272026-07-27
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
July 27, 2026
Johnson & Johnson
(Exact name of registrant as specified in its charter)
New Jersey
1-3215
22-1024240
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
732-524-0400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $1.00
JNJ
New York Stock Exchange
1.150% Notes Due November 2028
JNJ28
New York Stock Exchange
2.700% Notes Due February 2029
JNJ29B
New York Stock Exchange
3.200% Notes Due June 2032
JNJ32
New York Stock Exchange
3.050% Notes Due February 2033
JNJ33B
New York Stock Exchange
1.650% Notes Due May 2035
JNJ35
New York Stock Exchange
3.350% Notes Due June 2036
JNJ36A
New York Stock Exchange
3.350% Notes Due February 2037
JNJ37B
New York Stock Exchange
3.550% Notes Due June 2044
JNJ44
New York Stock Exchange
3.600% Notes Due February 2045
JNJ45
New York Stock Exchange
3.700% Notes Due February 2055
JNJ55
New York Stock Exchange
Item 7.01 Regulation FD Disclosure
On July 27, 2026, the Company announced that it has reached an agreement for a comprehensive resolution of the ovarian talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings, conditioned upon, among other things, the express participation of at least of 95% of the remaining claims. The agreement calls for per claim payments, with a $5.5 billion commitment by the Company, and the first payment of no more than $3 billion to be made in 2027 and no additional payments due before 2028. The press release further discussing this announcement is attached below as Exhibit 99.1.
Item 9.01 Financial statements and exhibits
(d) Exhibits.
Exhibit No. Description of Exhibit
99.1
Press Release dated July 27, 2026
104
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 27, 2026
JOHNSON & JOHNSON
(Registrant)
By:
/s/ Marc Larkins
Marc Larkins
Corporate Secretary
EX-99.1
EX-99.1
Filename: exhibit991.htm · Sequence: 2
Document
Exhibit 99.1
Media contact:
media-relations@its.jnj.com
Investor contact:
investor-relations@its.jnj.com
FOR RELEASE AT 6:15PM ET
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
Follows Favorable Multi-District Litigation Court Causation Ruling and the Company’s Successful Strategy to Defend Each Case
Efficient Conclusion to the Talc Litigation that Eliminates Expense Associated with Litigating Remaining 76,000 Ovarian Talc Claims
New Brunswick, N.J. – JULY 27, 2026 – Johnson & Johnson (NYSE: JNJ) (the "Company") today announced that it has reached an agreement for a comprehensive resolution of the remaining talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings, conditioned on, among other things, the express participation of at least 95% of the remaining claims. The proposed resolution follows a favorable ruling by the MDL court, and acknowledgment by plaintiffs’ counsel, regarding plaintiffs’ inability to prove that the Company’s talc products caused any particular claimant’s ovarian cancer (“specific causation”).
“After decades of litigation and full vetting of the science in an extensive hearing, plaintiffs effectively conceded their inability to prove specific causation by withdrawing their experts on the topic in two bellwether cases. In a watershed moment, the Court thereafter ordered plaintiffs to show why the remaining claims should not be dismissed, confirming what we have maintained for years: that these claims lack scientific merit and were sustained only by unreliable expert opinions that could not survive rigorous judicial review," said Erik Haas, Worldwide Vice President of Litigation, Johnson & Johnson. "The Court’s order placed plaintiffs in an untenable position of having to present specific causation evidence to maintain their claims that does not exist. While we are confident the Company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the Company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives."
The MDL Court’s recent specific causation ruling confirmed the Company's longstanding position that these claims lack scientific merit.
•The Company has prevailed in the overwhelming majority of ovarian cases tried to date.
•On July 22, 2026, the MDL court ordered plaintiffs to show why the remaining pending talc claims should not be dismissed for inability to prove specific causation.
•The order followed plaintiffs’ withdrawal of their specific causation experts in two bellwether cases, after a hearing that demonstrated their opinions were not based upon reliable scientific methodologies.
•The developments affirmed the Company’s longstanding position that the talc claims are premised on junk science that has been rejected for decades by United States scientific organizations and regulatory agencies, as well as independent experts.
The proposed resolution constitutes an efficient conclusion to the talc litigation.
The resolution:
•Requires and is conditioned on—among other criteria—the participation of lead plaintiff firms in all ovarian talc litigation pending in state and federal court, representing at least 95% of the remaining claims.
•Calls for per claim payments, with a $5.5 billion commitment by the Company and the first payment of no more than $3 billion to be made in 2027 and no additional payments due before 2028.
•Complements the progress the Company already has made to resolve the talc litigation, including previously settling about 95% of filed mesothelioma lawsuits, all State consumer protection claims, and all talc-supplier disputes.
•Brings finality to this meritless 15-year litigation.
Studies show talc is safe, does not contain asbestos and does not cause cancer.
•Research, clinical evidence, and decades of studies by independent medical experts around the world continue to support the safety of cosmetic talc.
•Prior to its separation, Johnson & Johnson agreed to retain all the talc-related liabilities and indemnify Kenvue for any and all costs—arising from litigation in the United States and Canada.
•As part of a worldwide portfolio assessment, Johnson & Johnson made the commercial decision to discontinue talc-based JOHNSON’S® Baby Powder globally in 2023. Additionally, Johnson & Johnson separated its consumer health business, Kenvue, in August 2023.
•Additional information on the Company's position and the science supporting the safety of talc is available at www.FactsAboutTalc.com.
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at www.jnj.com.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the proposed resolution of ovarian talc litigation. The reader is cautioned not to rely on these forward-looking statements. The information contained in this press release is for informational purposes only and should not be construed as a commitment by the Company to engage in any specific strategy or course of action. Due to the inherent uncertainty of litigation, the Company cannot predict the timing, ultimate outcome or financial impact of this matter, or any other ongoing or future litigation. The forward-looking statements in this press release are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: significant adverse litigation or government action, including related to product liability claims; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory actions; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. The Company expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.
GRAPHIC
GRAPHIC
Filename: image_0a.jpg · Sequence: 7
Binary file (244 bytes)
Download image_0a.jpg
GRAPHIC
GRAPHIC
Filename: image_1a.jpg · Sequence: 8
Binary file (17852 bytes)
Download image_1a.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 10
v3.26.1
Cover
Jul. 27, 2026
Cover [Abstract]
Document Period End Date
Jul. 27, 2026
Document Type
8-K
Entity Registrant Name
Johnson & Johnson
Entity Incorporation, State or Country Code
NJ
Entity File Number
1-3215
Entity Tax Identification Number
22-1024240
Entity Address, Address Line One
One Johnson & Johnson Plaza
Entity Address, City or Town
New Brunswick
Entity Address, State or Province
NJ
Entity Address, Postal Zip Code
08933
City Area Code
732
Local Phone Number
524-0400
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Document Information [Line Items]
Entity Emerging Growth Company
false
Entity Central Index Key
0000200406
Amendment Flag
false
Common Stock
Cover [Abstract]
Title of 12(b) Security
Common Stock, Par Value $1.00
Document Information [Line Items]
Title of 12(b) Security
Common Stock, Par Value $1.00
Trading Symbol
JNJ
Security Exchange Name
NYSE
Trading Symbol
JNJ
Security Exchange Name
NYSE
1.150% Notes Due November 2028
Cover [Abstract]
Title of 12(b) Security
1.150% Notes Due November 2028
Document Information [Line Items]
Title of 12(b) Security
1.150% Notes Due November 2028
Trading Symbol
JNJ28
Security Exchange Name
NYSE
Trading Symbol
JNJ28
Security Exchange Name
NYSE
1.650% Notes Due 2035
Cover [Abstract]
Title of 12(b) Security
1.650% Notes Due May 2035
Document Information [Line Items]
Title of 12(b) Security
1.650% Notes Due May 2035
Trading Symbol
JNJ35
Security Exchange Name
NYSE
Trading Symbol
JNJ35
Security Exchange Name
NYSE
3.20% Notes Due June 2032
Cover [Abstract]
Title of 12(b) Security
3.200% Notes Due June 2032
Document Information [Line Items]
Title of 12(b) Security
3.200% Notes Due June 2032
Trading Symbol
JNJ32
Security Exchange Name
NYSE
Trading Symbol
JNJ32
Security Exchange Name
NYSE
3.350% Notes Due June 2036
Cover [Abstract]
Title of 12(b) Security
3.350% Notes Due June 2036
Document Information [Line Items]
Title of 12(b) Security
3.350% Notes Due June 2036
Trading Symbol
JNJ36A
Security Exchange Name
NYSE
Trading Symbol
JNJ36A
Security Exchange Name
NYSE
3.550% Notes Due June 2044
Cover [Abstract]
Title of 12(b) Security
3.550% Notes Due June 2044
Document Information [Line Items]
Title of 12(b) Security
3.550% Notes Due June 2044
Trading Symbol
JNJ44
Security Exchange Name
NYSE
Trading Symbol
JNJ44
Security Exchange Name
NYSE
2.700% Notes due February 2029
Cover [Abstract]
Title of 12(b) Security
2.700% Notes Due February 2029
Document Information [Line Items]
Title of 12(b) Security
2.700% Notes Due February 2029
Trading Symbol
JNJ29B
Security Exchange Name
NYSE
Trading Symbol
JNJ29B
Security Exchange Name
NYSE
3.050% Notes due February 2033
Cover [Abstract]
Title of 12(b) Security
3.050% Notes Due February 2033
Document Information [Line Items]
Title of 12(b) Security
3.050% Notes Due February 2033
Trading Symbol
JNJ33B
Security Exchange Name
NYSE
Trading Symbol
JNJ33B
Security Exchange Name
NYSE
3.350% Notes due February 2037
Cover [Abstract]
Title of 12(b) Security
3.350% Notes Due February 2037
Document Information [Line Items]
Title of 12(b) Security
3.350% Notes Due February 2037
Trading Symbol
JNJ37B
Security Exchange Name
NYSE
Trading Symbol
JNJ37B
Security Exchange Name
NYSE
3.600% Notes due February 2045
Cover [Abstract]
Title of 12(b) Security
3.600% Notes Due February 2045
Document Information [Line Items]
Title of 12(b) Security
3.600% Notes Due February 2045
Trading Symbol
JNJ45
Security Exchange Name
NYSE
Trading Symbol
JNJ45
Security Exchange Name
NYSE
3.700% Notes due February 2055
Cover [Abstract]
Title of 12(b) Security
3.700% Notes Due February 2055
Document Information [Line Items]
Title of 12(b) Security
3.700% Notes Due February 2055
Trading Symbol
JNJ55
Security Exchange Name
NYSE
Trading Symbol
JNJ55
Security Exchange Name
NYSE
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details
Name:
dei_DocumentInformationLineItems
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDueNovember2028Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDueMay2035Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A3.20NotesDueJune2032Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A3.350NotesDueJune2036Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A3.550NotesDueJune2044Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A2.700NotesDueFebruary2029Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A3.050NotesDueFebruary2033Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A3.350NotesDueFebruary2037Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A3.600NotesDueFebruary2045Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=jnj_A3.700NotesDueFebruary2055Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type: